KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancerJianming Xu, Qian Wang, Xiaoyan Lin et al.|European Journal of Cancer|2022Cited by 54
A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.Chunmei Bai, Jin Li, Junli Xue et al.|Journal of Clinical Oncology|2024Cited by 16
The preliminary efficacy of KN026 (Anti-HER2 BsAb) in advanced gastric and gastroesophageal junction cancer patients with HER2 expression.Jianming Xu, Ting Xu, Yun Zhang et al.|Journal of Clinical Oncology|2021Cited by 13
A phase II study evaluating KN026 monotherapy in patients (pts) with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancers (GC/GEJC).Jianming Xu, Qian Wang, Rongrui Liu et al.|Journal of Clinical Oncology|2022Cited by 6
Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors.Jifang Gong, Lin Shen, Lei Chen et al.|Journal of Clinical Oncology|2023Cited by 6